American Depositary Shares, each representing 80,000 Ordinary Shares
- Symbol
- AKTX
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Current Report · Items 5.07, 9.01 · 8-K
Akari Therapeutics Plc
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On October 28, 2026, Akari Therapeutics, Plc (the “Company”) held a General Meeting (the “Special General Meeting”). Proxies were solicited pursuant to the Company’s Proxy Statement, filed with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended.…
Company context
We are an oncology company developing next-generation antibody-drug conjugates, or ADCs, designed around novel proprietary cancer-killing toxins, or payloads. We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
Current securities
Registered securities in this filing
Akari Therapeutics, Plc · 8-K · Filed 2026-10-30
Ordinary Shares, par value $0.000000005 per share*
- Symbol
- Not supplied
- Exchange
- Not supplied
- Classification
- COMMON
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
October 28, 2026, Akari Therapeutics, Plc (the “Company”) held a General Meeting (the “Special General Meeting”).
Proxies were solicited pursuant to the Company’s Proxy Statement, filed with the Securities and Exchange Commission under
Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares entitled to vote at the Special General
Meeting was 186,091,889,533. The number of ordinary shares present or represented by valid proxy at the Special General Meeting established
a quorum for the Special General Meeting. The Special General Meeting duly proceeded in accordance with the provisions of the articles
of association of the Company.
The
voting results below are final and reported in ordinary shares.
Ordinary Resolution For Against Abstain
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the 2023 Plan by 144,000,000,000 ordinary shares (the equivalent of 1,800,000 American Depositary Shares (“ADSs”)) from 19,806,000,000 ordinary shares to an aggregate of 163,806,000,000 ordinary shares (the equivalent of 2,047,575 ADSs) under the 2023 Plan plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under th... 79,142,490,228 1,314,720,000 22,005,228